Sairopa reports research milestones achieved in partnership with Exelixis, totalling $35 Million from consecutive clinical milestone payments in 2024
Sairopa B.V. has achieved a significant milestone in its partnership with Exelixis (NASDAQ: EXEL) regarding ADU-1805, an anti-SIRPα antibody for cancer treatment. The collaboration has generated substantial payments, including a $40 million upfront payment, $35 million for IND clearance, and an additional $35 million in clinical development milestones. The agreement grants Exelixis an exclusive option for worldwide development and commercialization rights following phase 1 clinical studies data review.
ADU-1805 is currently in a first-in-human phase 1 study across the U.S. and Europe, evaluating both monotherapy and combination treatment with pembrolizumab. The partnership combines Exelixis' oncology expertise with Sairopa's immunotherapy capabilities.
Sairopa B.V. ha raggiunto un traguardo significativo nella sua partnership con Exelixis (NASDAQ: EXEL) riguardo a ADU-1805, un anticorpo anti-SIRPα per il trattamento del cancro. La collaborazione ha generato pagamenti sostanziali, tra cui un pagamento iniziale di 40 milioni di dollari, 35 milioni di dollari per l'approvazione IND e ulteriori 35 milioni di dollari in traguardi di sviluppo clinico. L'accordo conferisce a Exelixis un'opzione esclusiva per i diritti di sviluppo e commercializzazione a livello mondiale dopo la revisione dei dati degli studi clinici di fase 1.
ADU-1805 è attualmente in uno studio di fase 1 su esseri umani negli Stati Uniti e in Europa, valutando sia la monoterapia che il trattamento combinato con pembrolizumab. La partnership unisce l'expertise oncologica di Exelixis con le capacità immunoterapiche di Sairopa.
Sairopa B.V. ha alcanzado un hito significativo en su asociación con Exelixis (NASDAQ: EXEL) respecto a ADU-1805, un anticuerpo anti-SIRPα para el tratamiento del cáncer. La colaboración ha generado pagos sustanciales, incluyendo un pago inicial de 40 millones de dólares, 35 millones de dólares por la aprobación IND y otros 35 millones de dólares en hitos de desarrollo clínico. El acuerdo otorga a Exelixis una opción exclusiva para los derechos de desarrollo y comercialización a nivel mundial tras la revisión de los datos de los estudios clínicos de fase 1.
ADU-1805 se encuentra actualmente en un estudio de fase 1 en humanos en EE.UU. y Europa, evaluando tanto la monoterapia como el tratamiento combinado con pembrolizumab. La asociación combina la experiencia oncológica de Exelixis con las capacidades de inmunoterapia de Sairopa.
Sairopa B.V.는 Exelixis (NASDAQ: EXEL)와의 파트너십에서 ADU-1805, 암 치료를 위한 항-SIRPα 항체와 관련하여 중요한 이정표를 달성했습니다. 이번 협력은 4천만 달러의 선불금, 3천5백만 달러의 IND 승인 비용, 그리고 추가로 3천5백만 달러의 임상 개발 이정표 등 상당한 금액의 지급을 생성했습니다. 이 계약은 Exelixis에게 1상 임상 연구 데이터 검토 후 전 세계 개발 및 상용화 권리에 대한 독점 옵션을 부여합니다.
ADU-1805는 현재 미국 및 유럽에서 사람을 대상으로 한 1상 연구 중에 있으며, 단독 요법과 pembrolizumab과의 병용 치료를 평가하고 있습니다. 이 파트너십은 Exelixis의 종양학 전문성과 Sairopa의 면역치료 능력을 결합합니다.
Sairopa B.V. a atteint un tournant significatif dans son partenariat avec Exelixis (NASDAQ: EXEL) concernant ADU-1805, un anticorps anti-SIRPα pour le traitement du cancer. La collaboration a généré des paiements substantiels, y compris un paiement initial de 40 millions de dollars, 35 millions de dollars pour l'approbation de l'IND, et un autre 35 millions de dollars en jalons de développement clinique. L'accord accorde à Exelixis une option exclusive pour les droits de développement et de commercialisation dans le monde entier après examen des données des études cliniques de phase 1.
ADU-1805 est actuellement en étude de phase 1 chez l'homme aux États-Unis et en Europe, évaluant à la fois la monothérapie et le traitement combiné avec pembrolizumab. Le partenariat associe l'expertise en oncologie d'Exelixis aux capacités d'immunothérapie de Sairopa.
Sairopa B.V. hat einen bedeutenden Meilenstein in der Partnerschaft mit Exelixis (NASDAQ: EXEL) bezüglich ADU-1805, einem Anti-SIRPα-Antikörper zur Krebsbehandlung, erreicht. Die Zusammenarbeit hat erhebliche Zahlungen generiert, darunter eine Vorauszahlung von 40 Millionen US-Dollar, 35 Millionen US-Dollar für die IND-Abwicklung und zusätzlich 35 Millionen US-Dollar in klinischen Entwicklungsmeilensteinen. Die Vereinbarung gewährt Exelixis eine exklusive Option für die weltweiten Entwicklungs- und Vermarktungsrechte nach der Überprüfung der Studiendaten der Phase-1-Studien.
ADU-1805 befindet sich derzeit in einer ersten Phase-1-Studie mit Menschen in den USA und Europa, in der sowohl die Monotherapie als auch die Kombinationstherapie mit Pembrolizumab bewertet werden. Die Partnerschaft kombiniert die onkologische Expertise von Exelixis mit den Immuntherapie-Fähigkeiten von Sairopa.
- Received total payments of $110 million from Exelixis to date
- Successfully achieved clinical development milestones
- Ongoing phase 1 trials in multiple countries
- Potential for additional milestone payments through development progression
- No clinical efficacy data reported yet
- Final licensing agreement with Exelixis still pending phase 1 data review
Insights
Under the terms of the agreement, Exelixis has an exclusive option to license worldwide development and commercialization rights for ADU-1805 and other anti-SIRPα antibodies following the review of data from Sairopa's phase 1 clinical studies. As part of its collaboration with Exelixis, Sairopa has previously received from Exelixis an upfront payment of
"Today's operational update signifies a step forward in the partnered effort to develop next-generation therapies for cancer patients worldwide," said Gurvinder S. Chahal, Chief Business Officer of Sairopa. "The advances seen within our clinical program are a testament to the diligent work and innovative science behind our partnership with Exelixis, bringing us closer to realizing our mission of modulating the immune system to improve outcomes for cancer patients."
The safety and pharmacokinetics of ADU-1805 are currently being evaluated in a first-in-human, open-label, multicenter, multi-arm phase 1 study. To date, patients have been enrolled across the
This collaboration combines Exelixis' proven track record in oncology drug development and commercialization with Sairopa's expertise in generating innovative cancer immunotherapies, setting the stage for potentially transformative treatments in oncology.
About Sairopa
Sairopa B.V. is a clinical-stage company focused on developing innovative treatments for cancer by modulating the patient's immune system. The pipeline features ADU-1604, an anti-CTLA4 antibody with promising safety and efficacy, having recently concluded a phase 1 study for PD-1 relapsed/refractory melanoma. A phase 2 trial with a PD-1 blocking antibody is planned for 2025. Additionally, Sairopa is advancing a SIRPα-PD-L1 bispecific antibody in preclinical development, aiming for an IND filing in 2026. With a portfolio of therapeutic antibodies developed from groundbreaking research and proprietary platforms, Sairopa aims to lead the way in the development of effective cancer immunotherapies. For more information about Sairopa, please visit www.sairopa.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the clinical and therapeutic potential of ADU-1805, ADU-1604 and the SIRPα-PD-L1 bispecific antibody, along with Sairopa's future plans and potential for clinical and commercial success. These forward-looking statements are based on the companies' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties.
Sairopa B.V.
CIC Stationsplein 45
Unit A4.004
3013 AK
View original content:SOURCE Sairopa B.V.
FAQ
How much has Exelixis (EXEL) paid Sairopa in total for the ADU-1805 partnership?
What are the current clinical trial stages for ADU-1805 under the EXEL partnership?
What rights does Exelixis (EXEL) have regarding ADU-1805?
What is the mechanism of action for ADU-1805 in Exelixis' (EXEL) pipeline?
